Results 21 to 30 of about 93,898 (384)
Severe Eosinophilic Asthma [PDF]
Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of constant research because it greatly affects patients’ quality of life, and patients with severe asthma experience symptoms, exacerbations, and medication side effects.
Bakakos, A., Loukides, S., Bakakos, P.
openaire +3 more sources
Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
Severe asthma can be associated with eosinophilic or allergic phenotypes or both. Eosinophilic inflammation is associated with exacerbations and disease severity due to biological activity of interleukin‐5 (IL‐5).
Venkata Nagarjuna Maturu +7 more
doaj +1 more source
Biomarkers for severe eosinophilic asthma [PDF]
The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic
Yancey, S +6 more
openaire +3 more sources
Although eosinophilic inflammation is characteristic of asthma pathogenesis, neutrophilic inflammation is also marked, and eosinophils and neutrophils can coexist in some cases. Based on the proportion of sputum cell differentiation, asthma is classified
Akira Yamasaki +2 more
doaj +1 more source
Introduction Asthma is a heterogenous disease with various phenotypes that is characterized by airway limitation due to bronchospasm and airway inflammation associated with excessive mucus secretion.
Maged Mohamed Refaat +3 more
doaj +1 more source
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source
Severe eosinophilic asthma [PDF]
A task force has identified key consensus issues for defining, diagnosing and treating severe eosinophilic asthmahttp://ow.ly ...
Buhl, Roland +21 more
openaire +5 more sources
Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study [PDF]
Background Asthma exacerbations are frequently triggered by rhinovirus infections. Both asthma and respiratory tract infection can activate haemostasis. Therefore we hypothesized that experimental rhinovirus-16 infection and asthmatic airway inflammation
Bel, EHD +12 more
core +23 more sources
Background The prevalence of eosinophilic asthma in Lebanon, one of the most severe phenotypes among severe asthma, is not known. This study aimed at determining the prevalence of the eosinophilic phenotype defined as an eosinophil count ≥ 300 cells/mm3 ...
Wajdi Abi Saleh +20 more
doaj +1 more source
Background: Severe eosinophilic asthma decreases lung function and causes worsen symptoms, often forcing recurrent maintenance corticosteroid use. The aim of our real-life study was to evaluate the effectiveness of an add-on treatment with benralizumab ...
Giulia Scioscia +14 more
doaj +1 more source

